Gene therapy for colorectal cancer by an oncolytic adenovirus that targets loss of the insulin-like growth factor 2 imprinting system

BackgroundColorectal cancer is one of the most common malignant tumors worldwide. Loss of imprinting (LOI) of the insulin-like growth factor 2 (IGF2) gene is an epigenetic abnormality observed in human colorectal neoplasms. Our aim was to investigate the feasibility of using the IGF2 imprinting system for targeted gene therapy of colorectal cancer.ResultsWe constructed a novel oncolytic adenovirus, Ad315-E1A, and a replication-deficient recombinant adenovirus, Ad315-EGFP, driven by the IGF2 imprinting system by inserting the H19 promoter, CCCTC binding factor, enhancer, human adenovirus early region 1A (E1A) and enhanced green fluorescent protein (EGFP) reporter gene into a pDC-315 shuttle plasmid. Cell lines with IGF2 LOI (HCT-8 and HT-29), which were infected with Ad315-EGFP, produced EGFP. However, no EGFP was produced in cell lines with maintenance of imprinting (HCT116 and GES-1). We found that Ad315-E1A significantly decreased cell viability and induced apoptosis only in LOI cell lines in vitro. In addition, mice bearing HCT-8-xenografted tumors, which received intratumoral administration of the oncolytic adenovirus, showed significantly reduced tumor growth and enhanced survival.ConclusionsOur recombinant oncolytic virus targeting the IGF2 LOI system inhibits LOI cell growth in vitro and in vivo, and provides a novel approach for targeted gene therapy.

[1]  A. Efstratiadis,et al.  Parental imprinting of the mouse insulin-like growth factor II gene , 1991, Cell.

[2]  D. Hanahan,et al.  A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis , 1994, Nature.

[3]  A. Fattaey,et al.  An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.

[4]  A. Feinberg,et al.  Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability , 1998, Nature Medicine.

[5]  R. Jirtle,et al.  Genomic imprinting: implications for human disease. , 1999, The American journal of pathology.

[6]  K. Mitsuya,et al.  Multipoint imprinting analysis in sporadic colorectal cancers with and without microsatellite instability. , 2000, International journal of oncology.

[7]  H. Kawasaki,et al.  Analysis of Genomic Imprinting of Insulin-Like Growth Factor 2 in Colorectal Cancer , 2000, Oncology.

[8]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.

[9]  M. Hung,et al.  E1A: Tumor suppressor or oncogene? Preclinical and clinical investigations ofE1A gene therapy , 2001, Breast cancer.

[10]  D. Kirn.  Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of Phase I and II trials , 2001, Expert opinion on biological therapy.

[11]  T. He,et al.  Adenoviral vector-mediated gene transfer for human gene therapy. , 2001, Current gene therapy.

[12]  R. Warren,et al.  Intravascular adenoviral agents in cancer patients: Lessons from clinical trials , 2002, Cancer Gene Therapy.

[13]  K. Hunt,et al.  Adenoviral gene therapy. , 2002, The oncologist.

[14]  W. Vandertop,et al.  Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. , 2002, Cancer research.

[15]  P. Working,et al.  Selectively replicating oncolytic adenoviruses as cancer therapeutics. , 2002, Current opinion in molecular therapeutics.

[16]  Y. Mishina,et al.  Heterozygosity with respect to Zfp148 causes complete loss of fetal germ cells during mouse embryogenesis , 2003, Nature Genetics.

[17]  Qun Zhou,et al.  Viral vectors for cancer gene therapy: viral dissemination and tumor targeting. , 2005, Current gene therapy.

[18]  S. Elledge,et al.  The APC/C and CBP/p300 cooperate to regulate transcription and cell-cycle progression , 2005, Nature.

[19]  Hui Ling Chen,et al.  CTCF Mediates Interchromosomal Colocalization Between Igf2/H19 and Wsb1/Nf1 , 2006, Science.

[20]  Ji-fan Hu,et al.  Correction of aberrant imprinting of IGF2 in human tumors by nuclear transfer‐induced epigenetic reprogramming , 2006, The EMBO journal.

[21]  T. Shirakawa.  The current status of adenovirus-based cancer gene therapy. , 2008, Molecules and cells.

[22]  A. Hoffman,et al.  CTCF Regulates Allelic Expression of Igf2 by Orchestrating a Promoter-Polycomb Repressive Complex 2 Intrachromosomal Loop , 2008, Molecular and Cellular Biology.

[23]  Xianqun Fan,et al.  Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  W. Tansey,et al.  Adenoviral E1A function through Myc. , 2009, Cancer research.

[25]  V. Corces,et al.  CTCF: Master Weaver of the Genome , 2009, Cell.

[26]  R. Cattaneo.  Paramyxovirus Entry and Targeted Vectors for Cancer Therapy , 2010, PLoS pathogens.

[27]  T. Cripe,et al.  Oncolytic virotherapy reaches adolescence , 2010, Pediatric blood & cancer.

[28]  Bangshun He,et al.  Targeted tumor gene therapy based on loss of IGF2 imprinting , 2010, Cancer biology & therapy.

[29]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[30]  Q. Qian,et al.  Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene , 2011, Gene Therapy.

[31]  A. Hemminki,et al.  Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. , 2011, Molecular pharmaceutics.

[32]  A. Hoffman,et al.  Interruption of intrachromosomal looping by CCCTC binding factor decoy proteins abrogates genomic imprinting of human insulin-like growth factor II , 2011, The Journal of cell biology.

[33]  A. Hemminki,et al.  Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  V. Monsurrò,et al.  Adenovirus as a new agent for multiple myeloma therapies: Opportunities and restrictions , 2011, The Korean journal of hematology.

[35]  Xianqun Fan,et al.  Potentiation of tumor radiotherapy by a radiation‐inducible oncolytic and oncoapoptotic adenovirus in cervical cancer xenografts , 2012, International journal of cancer.